Case Presentation: For this 18-year-old woman, the pregnancy ended but the diagnosis never did. Eighteen months after an eclamptic delivery, she presented with occipital headache, photophobia, and a generalized tonic–clonic seizure. In the intervening months, she had difficult blood pressure and recurrent seizures, repeatedly framed as lingering eclampsia and post-pregnancy hypertension despite escalating polypharmacy. On arrival, her blood pressure was 234/183 mmHg with sinus tachycardia; she was briefly post-ictal but quickly recovered a non-focal neurologic exam. Labs revealed mild acute kidney injury, proteinuria, and elevated cardiac biomarkers. Brain MRI showed parieto-occipital FLAIR hyperintensities consistent with posterior reversible encephalopathy syndrome (PRES). Transthoracic echocardiography demonstrated asymmetric left ventricular hypertrophy with papillary muscle hypertrophy, raising concern for hypertrophic cardiomyopathy or Fabry disease. CTA excluded coarctation and renovascular disease, and a comprehensive cardiomyopathy/metabolic genetic panel was negative. Autoimmune testing then revealed a high-titer speckled ANA, markedly elevated anti-U1 RNP, low complement, and a positive lupus anticoagulant, establishing mixed connective tissue disease with SLE overlap and antiphospholipid activity. Hydralazine was discontinued, hydroxychloroquine was started, and her antihypertensive regimen was streamlined and intensified. Blood pressure improved, seizures ceased, and, from her perspective, the story finally shifted from your pregnancy never ended, to; you have an autoimmune vasculopathy we can treat.
Discussion: This case showcases malignant hypertension and PRES as the first recognized manifestation of mixed connective tissue disease in a young woman whose narrative had been locked into a remote pregnancy complication. It is a clear example of anchoring bias on the prior diagnosis of eclampsia: once that label was applied, subsequent blood pressure spikes, seizures, and even PRES episodes were fit back into an obstetric frame, despite timing and multi-organ involvement incompatible with typical postpartum physiology. Asymmetric hypertrophy and papillary muscle prominence pushed the team toward genetic cardiomyopathy and Fabry disease, but negative genetic testing plus hypocomplementemia and antiphospholipid activity instead pointed to autoimmune vasculopathy with hypertensive remodeling. For hospitalists, her sense of not being heard is not just an emotional footnote; it is a clinical signal that the prevailing explanation is misaligned with the lived course. When a patient keeps returning with severe physiology and a story that no longer fits, it should trigger deliberate de-anchoring and expansion of the differential.
Conclusions: In young women with prior eclampsia, persistent postpartum hypertension, seizures, PRES, and unexplained cardiac remodeling beyond the early postpartum window should prompt evaluation for autoimmune vasculopathy, including mixed connective tissue and antiphospholipid syndromes. Hospitalists must actively guard against anchoring on obstetric labels, use negative genetic workups and patient-reported discordance as cues to reframe the problem, and pivot from purely hemodynamic control toward disease-modifying therapy to prevent irreversible cardio-neuro-renal injury.
.png)